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Cyclosporine toxicity on cultured rat microvascular endothellal cells.
The present study was undertaken to study the mechanism of cyclo-
sporine-induced nephrotoxicity and hypertension. Cultured rat micro-
vascular endothelial cells were exposed to cyclosporine for up to six
days at one of the following concentrations: 10, 50, 250, and 1000 nglml
of culture medium. Cyclosporine inhibited endothelial cell replication in
a dose.dependent manner; at higher concentrations (250 and 1000 ng/
ml), cell replication decreased by as much as 70 to 90% of controls at
four and six days post-treatment, with no evidence of increased cell
death. Drug-treated endothelial cells revealed abnormal morphological
changes such as formation of cytoplasmic vesicles and nucleolar
changes. Prostacyclin release by endothelial cells was increased by
about threefold with the addition of cyclosporine (P < 0.01). Indometh-
acm significantly decreased prostacyclin release by endothelial cells in
the presence or absence of cyclosporine (P < 0.01). Our data suggest
that cyclosporine-induced nephrotoxicity may be mediated, at least
partly, by the inhibitory influence of cyclosporine on the regenerative
response of microvascular endothelial cells to injury, and the resultant
alterations in prostacyclin production by these cells.
Cyclosporin A, an active endecapeptide of fungal origin, is a
potent immunosuppressive agent in widespread use for prolong-
ing the survival of various allogeneic organ transplants [1—4]. Its
immunosuppressive action is predominantly mediated by the
inhibition of T-helper cell production of interleukin 2, a T-ceIl
growth factor essential for B cell and cytotoxic T cell prolifer-
ation [1, 2]. While it has become the immunosuppressant of
choice in clinical transplantation in the eighties, cyclosporine
therapy can be complicated by several adverse effects including
nephrotoxicity, hepatotoxicity, and hypertension [1—7]. Of all
the known complications, nephrotoxicity is the most frequent
and clinically important, and may ultimately limit the use of
cyclosporine [5—8]. Cyclosporine-induced nephrotoxicity is of-
ten accompanied by decreased glomerular filtration rate and
proximal tubular damage [7, 81. The morphological changes
range from toxic tubulopathy manifested by nonspecific vacuo-
lization, swelling of endoplasmic reticulum and mitochondria in
tubular epithelial cells, to capillary congestion and arteriolo-
pathy [7—10]. In an animal model, cyclosporine treatment
induced endothelial injury, capillary thrombosis, and glomeru-
lar infarction similar to that seen in a generalized Schwartzman
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reaction [11, 12], This and other reports have led some inves-
tigators to propose that cyclosporine inhibits the synthesis of a
prostacyclin-stimulating factor in the kidney, thereby leading to
decreased production of prostacyclin by endothelial cells [11—
13]. Prostacyclin is a potent antagonist of thromboxane-medi-
ated platelet aggregation and subsequent thrombosis; it also
plays an important role in renal autoregulation by acting as a
physiologic antagonist to the vasoconstrictive effect of angio-
tensin II [14—16]. Thus, decreased prostacyclin production may
partly explain the hypertension and accelerated renal arteriolar
lesions induced by cyclosporine. Although it appears that
endothelial injury is an important feature of cyclosporine-
induced nephrotoxicity, the mechanism of cyclosporine-in-
duced nephrotoxicity clearly requires further elucidation. The
purpose of the present study was to examine whether cyclo-
sporine has a direct influence on the growth, morphological,
and biochemical characteristics of microvascular endothelial
cells in culture.
Methods
Isolation and culture ofadipose microvascular endothelial
cells
Microvascular endothelial cells were isolated from retro-
peritoneal adipose tissue of adult male Sprague—Dawley rats
(150 to 200 g) as reported previously [171. Briefly, fat tissue
resected aseptically from rats was digested with 0.5 mg/mI
collagenase (Type I, Worthington Biochemicals, Freehold,
New Jersey, USA) in Hanks' balanced salt solution (HBSS) for
30 minutes at 37°C, with continuous agitation in a gyrotory
waterbath shaker (New Brunswick Scientific, Edison, New
Jersey, USA). The cell suspension was filtered through a 250
pm nylon sieve (Nitex) to remove undigested fat, and the
filtrate was centrifuged at 300 x g for 10 minutes. The cell pellet
was resuspended in alpha minimum essential medium (MEM)
supplemented with 10% fetal bovine serum (FBS) (Gibco Can-
ada, Burlington, Ontario, Canada), and antibiotics (penicillin
100 mg/ml and streptomycin 50 mg/ml). Adipocyte precursors
were separated from the endothelial cell clumps by passing the
cell suspension through a 25 m nylon mesh (Nitex). The
endothelial cell clumps left on the sieve were inoculated into
culture vessels (Corning Culture Products, Corning, New York,
USA) and grown in complete alpha MEM supplemented with
10% FBS, 15 mM HEPES, and antibiotics, in a humidified 95%
air-5% CO2 atmosphere at 37°C. Colonies of endothelial cells
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formed in the first three to five days were detached from
primary culture with the aid of cloning cylinders and 0.5 mg/mI
trypsin-0.25 mi EDTA solution, and subcultured. Homoge-
neous cell strains of microvascular endothelial cells were ob-
tained beginning with the first subculture [17]. Cells were grown
to monolayer confluence and propagated in subcultures. Our
cultured microvascular endothelial cells have been character-
ized and reported in detail [17]. Briefly, endothelial cells were
distinguished by various markers: the characteristic cobble-
stone appearance on light microscopy and presence of Weibel-
Palade bodies on electron microscopic examinations; positive
staining for Factor VIII antigen by immunofluorescence; and
prostacyclin production by radioimmunoassay [17, 18]. In all
the experiments described herein, microvascular endothelial
cells between the second and fifth subcultures were used, and
their Factor VIII antigen positivity was monitored regularly.
Cultured rat skin fibroblasts and preadipocytes were used as
negative controls for Factor VIII antigen staining.
Influence of cyclosporine on endothelial ce/i groo'th
Cells were seeded at a density of 7,000 cells/cm2 into each
well of 24-well plates, and grown in alpha MEM with 10% FBS.
Forty-eight hours later, cyclosporine (Sandoz, Montreal, PQ,
Canada) 50 mg/mI in cremophor was diluted I: 100 with 50 mgI
ml glucose solution and added immediately before use) was
added in quadruplicates to each cell culture at one of the
following concentrations: 10, 50, 250, or 1000 ng/ml of culture
medium. The dose range of cyclosporine used in this study was
similar to those used by others in cell culture studies [19], and
was within the peak and nadir therapeutic plasma levels re-
ported in patients receiving the medication either orally or
intravenously [20, 21], Control cells were not exposed to
cyclosporine; the corresponding volume of carrier (cremophor
in 50 mg/mI glucose solution) was added instead. The growth,
morphological, and biochemical characteristics of the endothe-
hal cells were assessed in both control and drug-treated groups
daily for a total of six days. Cell replication was assessed by
both direct cell counting using a Model ZM Coulter counter
(Coulter Electronics of Canada, Burlington. Ontario, Canada),
and by incorporation of [methyl-3H]thymidine into trichloro-
acetic-acid-insoluble macromolecules (DNA), as previously de-
scribed [17, 18, 221.
The incorporation of [3H]thymidine into trichloroacetic-acid-
insoluble macromolecules in control and cyclosporine-treated
endothelial cells was quantified by adding 0.25 pCi [1H]thy-
midine (Amersham Canada Ltd., Oakville, Ontario. Canada)
and 0.375 g unlabelled thymidine (Sigma Chemical Co., St.
Louis, Missouri, USA) to the cell culture. Sixteen to 20 hours
later, cells in each culture well were washed thrice with
phosphate-buffered saline (PBS), and detached from the vessel
with 0.5 mg/mI trypsin-0.25 mri EDTA solution. The cell
suspension was transferred to a sampling manifold (Millipore
Corporation, Bedford, Massachusetts, USA) fitted with What-
man GF/1 glassfiber filters, and was thoroughly washed with 30
ml 10% trichloroacetic acid. The radioactivity incorporated into
the trichloroacetic-acid-insoluble macromolecules, which was
retained on the filters, was counted in 5 ml Econofluor scintil-
lation fluid (New England Nuclear, Lachine, PQ, Canada) in a
LKB RackBeta liquid scintillation spectrophotometer (LKB-
Produkete AB, Bromma, Sweden).
Cell viability was assessed under light microscopy by quan-
tifying the percentage of cells, using a hemocytometer, that
actively excluded 0.1% Trypan blue dye in 0.9% saline [18].
Electron microscopy
Cultured cells were scraped off the culture dish with a rubber
spatula and centrifuged at 300 x g for 10 minutes. The cell
pellets were fixed for one hour at room temperature in 2.5%
glutaraldehyde-l% osmium tetraoxide mixture in 0.1 M cacody-
late-buffer, pH 7.4, containing 0.1 M sucrose and 5 mi CaCI2.
The samples were dehydrated through graded acetone and
embedded in Epon. Selected areas were sectioned, stained with
uranyl acetate and lead citrate, and examined in a Hitachi
Model H600 electron microscope.
Effect of cyclosporine on Factor VIII antigen staining and
prostacyclin synthesis by endothelial cells
Prostacyclin (PGI2) production by cyclosporine-treated and
untreated endothelial cells was quantified by the release into the
culture medium of 6-keto-PGF1,, a stable catabolic product of
PGI,, using a radioimmunoassay kit (Amersham Canada Ltd.,
Oakville, Ontario, Canada) [18]. Previous experiments were
conducted to ensure that the amount of PG!2 assayed was well
within the detectable range of 0.008 to 1.4 pmoh/ml. Briefly, 100
l aliquots of either standard solution or unknown were incu-
bated with 100 d each of [3H]6-keto-PGF1, and 3,6-keto-PGF1
antiserum at room temperature for one hour, followed by
another 16 to 20 hour incubation at 4°C. Dextran-coated char-
coal was added to the assay tubes to bind the free 6-keto-
PGF1,. Following centrifugation at 1000 x g for 10 minutes at
4°C, the amount of bound [3H]6-keto-PGF1 in the supernatant
was quantified.
Since 10% FBS was required for optimal endothelial cell
growth, we conducted separate experiments to determine
whether FBS cross-reacted with the antibodies used in the PG!2
assay. We found that FBS did not interfere with the actual PGI2
assay.
To examine whether the cyclosporine-induced alterations in
PGI, production was due to a change in its release or synthesis,
we conducted a similar series of experiments, as described
above, in the presence or absence of l0— M indomethacin,
which is a known inhibitor of prostaglandin synthesis.
The influence of cyclosporine on the presence of Factor VIII
antigen in endothelial cells was examined by an immunofluo-
rescent staining technique [17]. For this study, microvascular
endothelial cells were grown on glass cover slips. At 2, 4, or 6
days following drug treatment (at the four concentrations as
described above), cells were washed with PBS and fixed in a
solution containing a I: I mixture of glacial acetic acid and
methanol. The cells were then washed thrice with PBS and
incubated at 37°C with rabbit antiserum to human Factor VIII
(Calbiochem, San Diego, California, USA) for about 16 to 20
hours. This was followed by a second incubation with a 1:20
solution of fluorescein-conjugated anti-goat IgG (Miles Labora-
tories, Inc., Naperville. Illinois, USA) at 37°C for one hour.
After extensive washings with PBS, the coverslips were
mounted on glass slides with para-phenylenediamine mounting
buffer [23]. Immunoreactivity to Factor VI!! was examined
under a Zeiss Model MC 63 fluorescent microscope (Excitation
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390—440 m, Filtration 460 pm, Barrier 474 m, Zeiss, Oberk-
ochen, FRG).
Using the unlabelled antibody peroxidase-antiperoxidase [24]
or avidin-biotin-peroxidase complex [25] technique, the fixed
slides were stained for vimentin, Factor VIII antigen, and for
ulex europalus I (Dako Corporation, Santa Barbara, California,
USA).
Statistical analysis
All data were analyzed by Student's paired f-test, and for
multiple comparisons, by Tukey's method [26].
Results
Morphological observations
Under normal culture conditions, endothelial cells formed
small colonies within two to three days following inoculation.
By 12 to 20 days, depending on the initial inoculum density,
these cells would reach monolayer confluence and display the
characteristic cobblestone appearance (Fig. 1A). There was no
appreciable change in the light microscopic appearance of
endothelial cells with low dose cyclosporine (10 to 50 nglml)
treatment for six days. However, abnormal changes were
readily observed in cells exposed to higher doses of cyclo-
sporine (250 and 1000 ng/ml), as shown in Figure lB. Despite
the morphological changes induced by cyclosporine, there was
no evidence of cell death, as assessed by Trypan blue exclu-
sion, even when the cells were exposed to the highest concen-
tration of cyclosporine. In fact, cell viability was over 95% for
both control and cyclosporine-treated cells throughout the
entire study period, with no statistical differences in cell viabil-
ity between cells on days 2 and 4, or between cells on days 2
and 6 of growth.
Light and electron microscopic examinations demonstrated
presence of cytoplasmic vacuoles as early as 48 hours following
drug exposure. These vacuolations appeared in greater number
with increasing dosage and duration of exposure to cyclo-
sporine (Fig. 2). The vacuoles were bound by a single unit
membrane containing either a small amount of amorphous
materials occasionally mixed with dense granules, or membra-
nous fragments with clusters of small organized round struc-
tures (Fig. 3). Other cytoplasmic organelles, such as mitochon-
dna, endoplasmic reticulum and Golgi apparatus, did not show
any significant abnormalities. When cells were exposed to 250
ng/ml or 1000 nglml cyclosporine for six days, the nucleoli of
some endothelial cells revealed segregation of nucleolar com-
ponents, resulting in formation of many electron-lucent areas
(Fig. 4).
Factor VIII antigen staining
Positive staining for Factor VIII antigen was present in both
cyclosporine-treated and untreated (control) endothelial cells
(Fig. 5), but not in control cells such as rat fibroblasts and
preadipocytes (data not shown). Furthermore, neither the pat-
tern nor the intensity of staining show any appreciable change
with cyclosporine during the entire length of the six day study
period.
Effect of cyclosporine on endothelial cell growth
Figure 6 shows the inhibition of cell replication by cyclo-
sporine expressed as a percent of control cells not exposed to
the drug. Cell replication was determined by direct cell counting
(Fig. 6A) and by incorporation of [3Hjthymidine into trichloro-
acetic-acid-insoluble macromolecules (DNA) (Fig. 6B). As
shown in this figure, cyclosporine inhibited the growth of
microvascular endothelial cells in a dose-dependent manner.
With low dose (10 nglml) cyclosporine, the inhibitory effect was
only evident after six days of incubation. However, significant
inhibition was observed as early as two days following exposure
to higher doses of cyclosporine. After six days of high-dose
cyclosporine treatment (1000 nglml), cell replication, as as-
sessed by direct cell enumeration and radioactive thymidine
incorporation into DNA, decreased to 38% and 21% of control,
respectively.
Prostacyclin release by microvascular endothelial cells
Prostacyclin (PGI2) release by microvascular endothelial
cells cultured in the absence or presence of cyclosporine is
shown in Table 1. In all cases the PG!2 present in the culture
media was well within the detectable range of the radioimmu-
noassay, The level of PG!2 present in the control cells were
comparable to that observed in endothelial cells from large
vessels [24]. Hence the amount of arachidonate present in the
10% FBS added to all our cell culture media did not appreciably
alter the basal state of PG!2 release by microvascular endothe-
hal cells. Since the total amount of PG!2 release into the culture
media increased progressively in all cells from days I to 6, we
chose to show only the data from days 2, 4, and 6 in Tables I
and 2. Statistically significant differences in PGI2 release by
both the untreated controls as well as in the cyclosporine-
treated cells were observed between 2 and 4 days, and between
4 and 6 days of growth. When comparing the PG!2 release by
control and cyclosporine-treated cells, statistical differences
were seen only in those cells exposed to high dose (250 and 1000
ng/ml) cyclosporine at 4 and 6 days of growth.
Since cyclosporine inhibited cell replication, the data were
also analyzed by expressing PG!2 release on the basis of cell
number instead of total amount present in each culture well.
There was no statistical difference in PG!2 release by any one
group of cells (control or drug-treated) between 2 and 4 days,
between 2 and 6 days, and between 4 and 6 days of growth
(Table 2). However, major differences were observed when
PG!2 release by control cells was compared with that by
drug-treated cells. Cyclosporine stimulated PG!2 release by
endothelial cells after four days of exposure in a dose-depen-
dent manner, with maximum stimulation seen at high dose
cyclosporine (1000 ng/ml). PGI2 release by cells grown in the
presence of high dose cyclosporine was about threefold greater
than that by control cells.
As shown in Table I, l0- M indomethacin, a known prosta-
glandin synthesis inhibitor, significantly reduced PG!2 release in
both control and cyclosporine-treated cells. These data sug-
gested that cyclosporine stimulated both PG!2 synthesis and
release by microvascular endothelial cells.
Discussion
The present study has demonstrated that cyclosporine exerts
direct effects on cultured microvascular endothelial cells. The
dose range of cyclosporine used in this study were within the
peak and nadir therapeutic plasma levels reported in patients
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Fig. 1. Light microscopy of rat microt'ascular endothelial cells grown under normal cu/lure conditions (A). Note the characteristic cobblestone
appearance at monolayer confluence (original x 100). B. The morphology of these cells in the presence of high dose (1000 ng/ml culture medium)
cyclosporine (x 100). Small cytoplasmic vacuoles are visible in many cells.
receiving the medication either orally or intravenously [20, 21J. high concentrations of cyclosporine were found in many organs
Similar cyclosporine concentrations have also been used in cell and tissues, notably liver, kidney, and retroperitoneal fat [20,
culture studies [19]. When administered to humans or animals, 21]. In fact, animal data show that levels of cyclosporine in
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Fig. 2. Electron photomicrograph of rat microvascu/ar endoihelial cells at day 2 of culture under (A) normal conditions (control), and(B) in the
presence of 50 nglml cyclosporine. Note the numerous large cyloplasmic vacuoles containing flocculomembranous and dense materials (arrows)
and the abundant normal niitochondria (M). Original x 21,000; bar 0.5 rm.
tissues are higher than those in blood or plasma [201. This is not cells derived from retroperitoneal fat tissue may reflect similar
unexpected in view of the lipophilic nature of cyclosporine. in vitro responses by renal glornerular endothelia.
Since renal glomerular endothelial cells have not yet been As demonstrated by Trypan Blue exclusion throughout the
successfully isolated, studies using microvascular endothelial entire study period, there was no change in cell viability even in
4••. - 4:
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Fig. 3. Electron micrograph of microvascular endothelial cells at day 6 of culture in the presence of 1000 nglml cyclosporine. Numerous large
cytoplasmic vacuoles (arrows) containing membrane fragments and clusters of tiny vesicles are evident. The ultrastructural appearance of these
vacuoles are compatible with phagolysosomes. Golgi apparatus (G) and abundant mitochondria (M) were not affected by drug treatment. Original
x 21,000; bar = 0.5 m.
cells exposed to high doses of cyclosporine. Although we did
not examine endothelial cells for leakage, other cell culture
studies failed to report any cyclosporine-induced cell leakage or
cytotoxicity [1, 2, 27—311. Hence, cyclosporine did not appear
to cause lethal effects or cell leakage in microvascular endothe-
hal cells in the range of concentrations tested.
Electron microscopy demonstrated nonspecific cytoplasmic
vacuolations with cyclosporine treatment. These ultrastructural
changes corresponded to the cytoplasmic vacuolations visible
on light microscopy. The observations are probably not artifac-
tual since they were not present in control cells processed under
identical conditions. Furthermore, the cytoplasmic changes
were dependent on the dosage and duration of drug exposure.
With high dose cyclosporine, the vacuoles appear to contain
membrane fragments and other organized materials. These
vacuoles resemble the morphological appearance of phagolyso-
somes, suggesting the sublethal damage of cyclosporine to
susceptible endothelial cells. More importantly, we did not
observe any swelling of or damage to mitochondria and other
cytoplasmic organelles by cyclosporine treatment. A previous
study on rats given very high doses of cyclosporine for three
weeks also reported similar ultrastructural damages in rat
proximal renal tubular cells [321. Unfortunately, glomerular
endothelial cells were not examined by the investigators in that
study. Our current findings are in sharp contrast from those of
other studies on renal glomerular and tubular cells of cyclo-
sporine-treated animals, which demonstrated mitochondrial
swelling in addition to cytoplasmic vacuolations [7—101. It is
possible that the observed mitochondrial swelling could be due
to artifacts caused by improper fixation and processing of tissue
samples.
The present findings indicate that cyclosporine is a potent
inhibitor of microvascular endothelial cell replication. Our
observations on inhibition of cell replication by cyclosporine
are similar to those previously reported in EL4 cells from a
thymic leukemia cell line, and murine islet cells [29, 31]. The
mechanism whereby cyclosporine influences cell proliferation
is not well understood. Cyclosporine does not prevent a cellular
response by merely coating the cell surface, but probably acts
via a series of specific intracellular events [1, 19]. Furthermore,
it does not appear to affect the activation of calcium-dependent
protein kinases or cyclic AMP-dependent protein kinases, at
least in T lymphoblastoid cell lines [19]. Recent studies suggest
that cyclosporine may bind to calmoduhin and act as a calmo-
duhin antagonist [30, 331. Thus, cell replication may be inter-
fered with through the calcium/calmodulin-dependent intracel-
lular pathways, resulting in disruption of the cytoskeletal
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Fig. 4. Nucleolar changes in microvascular
endothelial cells exposed to 1000 ng/ml
cyclosporine for 6 days. Note the lucent areas
devoid of nucleolar materials. Original x
31,000; bar = 10 m,
[30, 31, 33, 34].
Endothelial cells are an important source of prostacyclin
(PGI2), a potent vasodilator that also inhibits thromboxane-
mediated platelet aggregation [161. These properties of PGI2 are
thought to play important roles in protection against thrombosis
and atherosclerotic cardiovascular disease [161. Recent work
suggests that PGI2 may also have important implications for the
regulation of renovascular resistance and for interactions with
the renin-angiotensin system [14, 151. Indeed, PG!2 is capable
of stimulating the renin-angiotensin-aldosterone system, while
it also acts as a physiologic antagonist to angiotensin II in
In cultured endothelial cells, PGI2 production is stimulated
by exposure to a variety of agents, such as thrombin, trypsin,
and the calcium ionophore A23187 [381. Cyclosporine, like
some of these agents, also induces prostacyclin release by
microvascular endothelial cells in culture. In the present study,
the basal prostacyclin release by control cells was comparable
to levels reported in endothelial cells cultured from both large
and small vessels [17, 28]. In the presence of high dose
cyclosporine, prostacyclin release per cell increased to almost
threefold over the untreated controls. Since cyclosporine in the
range of concentrations tested was not cytotoxic, it is unlikely
Fig. 5. Positive immunoperoxidase staining of
microvascular endothelial cells demonstrating the
presence of Factor VIII antigen in the cytoplasm.
Cells were grown in the absence (A) or presence
of 1000 nglml cyclosporine (B) for 6 days (original
x 400). Cyclosporine did not alter the intensity
or pattern of staining for Factor VIII antigen.
However, cytoplasmic vacuoles are readily seen
in the drug-treated cells. Bar = 10 m.
further studies, may also partly explain the known inhibitory lowering systemic arterial blood pressure in animals [14—16, 35—












Table 1. Effect of cyclosporine on prostacyclin synthesis by microvascular endo thelial cells in vitro
Days of Prostacyclin synthesis pmol/ml
culture 2 4 6

















0.478 0.023 0.049 0.009
0.494 0.033 n.t.
0.437 0.023 0.032 0.006
0.413 0.018" 0.040 0.007











Prostacyclin release into the culture media was quantified daily for a total of 6 days. The representative data shown were obtained from 2. 4,
and 6 days following the addition of cyclosporine (CsA) at the dosages indicated. Data are expressed as mean SEM of6 experiments and analyzed
using Tukey's method for multiple comparisons.
n.d. = not detectable; and n.t. = not tested.
a The effect of iO M indomethacin (+ I) is shown in the corresponding columns.b Denotes statistical significance with P < 0.05 when compared with the respective controls.
that the increase in prostacyclin in the media could be attributed
to cell leakage or release by dying cells. Furthermore, the level
of prostacyclin release induced by cyclosporine was dose-
dependent, indicating a pharmacological effect on endothelial
cells. Since indomethacin inhibited prostacyclin release in the
culture medium, our current data implied that the cyclosporine-
induced increase in prostacyclin release by microvascular en-
dothelial cells is likely due to both increased synthesis and
crovascular endothelial cells, the intensity and pattern of posi-
tive staining for Factor VIII antigen is not appreciably altered.
This crude quantitative estimate may suggest that cyclosporine
does not influence the amount of Factor VIII antigen produc-
tion in small vessel endothelial cells.
The kidney, with its unique vascular supply and blood flow
characteristics, has the largest vascular endothelial surface
relative to weight of any organ in the body. Consequently,
A













Fig. 6. Effect of cyclosporine on replication of cultured rat microvascular endothelial cells determined by (A) direct cell counting, and (B)
incorporation of [3HJthymidine into DNA. Cyclosporine was added to culture wells, each containing an initial inoculum of 7,000 cells/cm2, at the
following concentrations: 10 (0), 50 (is), 250 (•), or 1000 (A) ng/ml of culture medium, The results were the means SEM of6 experiments, and
were expressed as percent of control values in both cases, Asterisks indicate statistical difference between the drug-treated and control cells
(* denotes P < 0.05, ** denotes P < 0.01) using Tukey's method of multiple comparisons.
2 4 6 2 4 6
release. exposure of the glomerular capillary network to toxic sub-
While cyclosporine induces prostacyclin production by mi- stances occurs with much higher frequency compared with
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Table 2. Effect of cyclosporine on prostacyclin synthesis by microvascular endothelial cells in vitro
Days of Prostacyclin synthesis pmol/105 cells
culture 2 4
Treatment + I + I
6
+ I
Control 1.43 0.14 n.d. 1.25 0.11 0.53 0.23 1.20 0.03 0.74 0.07
CsA nglml
10 1.73 0.12 n.t. 1.76 0.21 n.t. 1.47 0.19 n.t.
50 2.05 0.36 0.13 0.01 1.60 0.08a 0.18 0.02 1.67 0.07a 0.28 0.04
250 2.34 0.35 0.38 0.02 1.96 0.l4 0.21 0.02 2.26 0.26a 0.22 0.02
1000 2.77 0.49 0.24 0.03 3.16 0,l4 0.29 0.06 3.17 0.O6 0.50 0.03
Data are expressed as mean SCM of 6 experiments and analyzed using Tukey's method for multiple comparisons.Refer to Table 1 for
abbreviations and symbols.
Denotes statistical significance with P < 0.05 when compared with the respective controls.
other capillary beds. Nephrotoxins can also induce damage by
binding to renal tubular cells due to the unique transport
properties of these cells [37, 39]. Cyclosporine-induced neph-
rotoxicity in animals and humans is associated with abnormal
structural changes in capillary, or renal tubules, or both [7—10].
As a result, cyclosporine could lead to both acute and chronic
renal dysfunction. Divergent opinions exist with regards to
whether the cyclosporine-induced toxicity arises primarily from
endothelial damage, or from effects on tubular cells, or from
both. Recent in vivo and in vitro studies, however, have failed
to show any direct evidence of cyclosporine-induced injury on
renal tubular cell injury [37], thereby arguing against the con-
cept of cyclosporine-induced toxic renal tubular injury as a
primary event. Indeed, clinical studies on renal allograft recip-
ients are consistent with this view. It has been observed that the
urinary levels of the lysosomal enzyme, N-acetyl-/3-glucosa-
minidase (NAG), a sensitive marker of renal tubular injury,
does not differ between patients treated with cyclosporine and
those receiving azothiapnne, another immunosuppressant
which does not cause appreciable renal damage [37].
Changes in the renal vasculature have been the focus of more
recent studies on cyclosporine-induced toxicity. For example,
cyclosporine reduces renal blood flow when infused in rats and
humans [1, 2, 39], suggesting a predominant renovascular effect
of the drug.
Several studies have suggested that cyclosporine inhibits the
synthesis of a "prostacyclin-stimulating factor", possibly a
lymphokine, thereby reducing the production of prostacyclin by
the renal vascular endothelium [11—131. Based on this tenet,
endothelial injury in the presence of reduced PGI2 would then
progress to local capillary thrombosis and glomerular infarction
similar to that seen in the generalized Schwartzman reaction
[11, 12]. Experimental rabbit models have shown that cyclo-
sponne reduces prostacyclin generation by vessel wall [11, 121.
However, the source of production and identity of the so-called
"prostacyclin-stimulating factor" remains elusive. On the other
hand, some studies indicate that cyclosponne treatment is
associated with a stimulation of renal prostaglandin synthesis,
resulting in increased urinary excretion of prostacyclin [37].
These observations are supported by reports on the inhibition
of prostaglandin synthesis by indomethacin, leading to an
increase in renal toxicity with nontoxic doses of cyclosporine
[39, 40]. Furthermore, cyclosporine has been reported to stim-
ulate prostacyclin production in smooth muscle cells from
guinea pig aorta, presumably through enhanced arachidonic
acid release [411.
Our current data have clearly demonstrated that cyclosporine
has two direct effects on microvascular endothelial cells: inhi-
bition of cell replication and stimulation of prostacyclin release.
Similar effects may also occur in renal microvascular endothe-
hal cells. In view of our in vitro observations, it would be
tempting to speculate on the cellular mechanisms of cyclo-
sporine-induced nephrotoxicity and hypertension. Cyclo-
sporine has diverse actions on different cell types, as evident by
its multiple effects on various T lymphocytes [1—3]. Likewise,
the pathogenesis of cyclosponne-induced nephrotoxicity is
multifactoriaL It is conceivable that glomerular or capillary
endothelial injury may be an initial lesion occurring as a result
of anoxia or graft versus host disease. Since cyclosporine
inhibits cell replication and stimulates prostacyclin production
by endothelial cells, the overall effect of cyclosporine will
depend on the extent of endothelial injury in vivo. Total
prostacyclin production by renal endothelial cells may be
decreased, unchanged, or even increased. If production is
increased, which could occur if endothelial cell damage is
minimal, cyclosporine treatment may lead to activation of the
renin-angiotensin system and eventually hypertension [42].
This effect of cyclosporine may account for the experimental
observation of increased renin level with its use [35, 36],and the
increased incidence of hypertension in several clinical studies
[1—7]. On the other hand, through its direct inhibition on
endothelial cell replication, cyclosponne may potentiate gb-
merular endothelial injury in vivo by impairing the regenerative
response of endothelium to wound. This may result in alter-
ations in renal blood flow and glomerular filtration rate, both of
which are well documented [7, 81. Inhibition of endothelial cell
replication could also result in a decrease in total prostacyclin
production, as was observed in our experiments. Indeed, de-
creased urinary prostaglandins have been reported in patients
receiving cyclosporine therapy [43]. Coupled with its possible
toxic effect on the renal tubules, cyclosporine can generate a
vicious cycle ultimately resulting in further renal damage.
Further studies using cultured microvascular endothelial cells
will undoubtedly lend further insight into the molecular mech-
anisms of cyclosporine-induced prostacyclin synthesis by vas-
cular cells.
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